Sangtec highlights brain damage:
This article was originally published in Clinica
Executive Summary
Swedish company Sangtec Medical's Sangtec 100 was an effective prognostic marker of cerebral damage following myocardial revascularisation in a study conducted at Malmo University Hospital, Sweden, and the UK's Oxford Heart Centre. Brain damage occurs in around 6% of revascularisation patients.